| Revenue growth | Consolidated revenue up 17% YoY to ₹271.5 billion. |
|---|---|
| Margins | Record 31.2% EBITDA margin, 80 bps improvement YoY. |
| Demand visibility | Strong demand in India branded formulations and US specialty segments. |
| Management confidence | Extremely high following record margins and successful inorganic expansions. |
Growth
Double-digit organic growth across India and US markets, propelled by specialty launches and volume expansion in generic segments.
Outlook
Guided high-teens revenue growth for FY27 with EBITDA margins exceeding 24% despite heavy investment phases.
Risks
High base effect for FY27, increased competition in Revlimid, and rising R&D/commercialization costs for new launches.
Earnings Call filed with BSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,154.00
- Market cap
- ₹1,16,119 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 25.7×Sector 47.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
- Execution
- 52 weeks
Zydus Lifesciences Merger & Restructuring Worth ₹5 Cr
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
- Value
- ₹5.00 Cr
Zydus Lifesciences Promoter Buying (Off-Market)
Zydus Lifesciences announced the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both within the Promoter Group.